Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RePASS: Adjuvant Toripalimab in High-Risk Recurrent/Second Primary HNSCC
NCT04126460Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2019
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Disease-Free Survival at 1 year. Status: unknown.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04126460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126460.